NASDAQ:AMRN

Amarin (AMRN) Stock Price, News & Analysis

Amarin logo
$10.57 -0.69 (-6.13%)
Closing price 04:00 PM Eastern
Extended Trading
$10.56 -0.01 (-0.09%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Amarin Stock (NASDAQ:AMRN)

Advanced

Key Stats

Today's Range
$10.56
▼
$11.30
50-Day Range
$11.26
▼
$14.00
52-Week Range
$10.56
▼
$17.31
Volume
177,890 shs
Average Volume
76,552 shs
Market Capitalization
$222.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Sell

Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health. Its principal product is VASCEPA, a prescription medicine containing icosapent ethyl, an omega-3 fatty acid derivative.

In the United States, VASCEPA is approved for use with a statin and other measures to reduce the risk of certain cardiovascular events in eligible adults with elevated triglycerides. It is also approved as an adjunct to diet to lower triglyceride levels in adults with severe hypertriglyceridemia.

Amarin has also pursued markets outside the United States through partnerships. In Europe, icosapent ethyl is marketed under the name Vazkepa for eligible patients at high cardiovascular risk. The company’s business centers on developing and commercializing this treatment and supporting its use in cardiovascular care.

AI Generated. May Contain Errors.

Amarin Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

AMRN MarketRank™: 
1.74458459007 of 5 stars

Amarin scored higher than 35% of companies evaluated by MarketBeat, and ranked 732nd out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amarin has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 2 sell ratings.

  • Upside Potential

    Amarin has a consensus price target of $13.00, representing about 22.2% upside from its current price of $10.64.

  • Amount of Analyst Coverage

    Amarin has only been the subject of 2 research reports in the past 90 days.

  • Read more about Amarin's stock forecast and price target.
  • Earnings Growth

    Earnings for Amarin are expected to grow in the coming year, from ($0.85) to ($0.84) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amarin is -11.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amarin is -11.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amarin has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.66% of the float of Amarin has been sold short.
  • Short Interest Ratio / Days to Cover

    Amarin has a short interest ratio ("days to cover") of 7.58.
  • Change versus previous month

    Short interest in Amarin has recently increased by 0.98%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Amarin does not currently pay a dividend.

  • Dividend Growth

    Amarin does not have a long track record of dividend growth.

  • News Sentiment

    Amarin has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Amarin this week, compared to 4 articles on an average week.
  • Search Interest

    2 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amarin insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.21% of the stock of Amarin is held by insiders.

  • Percentage Held by Institutions

    22.25% of the stock of Amarin is held by institutions.

  • Read more about Amarin's insider trading history.
Receive AMRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMRN Stock News Headlines

Amarin Reports Immediate Resignation of Company Director
Amarin Earnings Call Highlights Profitability and Global Growth
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Amarin (NASDAQ:AMRN) Stock Moved Up to Buy by Wall Street Zen
Amarin: 3 Key Takeaways for Long-Term Investors
See More Headlines

AMRN Stock Analysis - Frequently Asked Questions

Amarin's stock was trading at $13.95 at the start of the year. Since then, AMRN stock has decreased by 23.8% and is now trading at $10.6350.

Amarin Corporation PLC (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, February, 25th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($1.27) by $1.28. The biopharmaceutical company had revenue of $49.22 million for the quarter, compared to analyst estimates of $50.62 million. Amarin had a negative net margin of 10.87% and a negative trailing twelve-month return on equity of 0.52%.
Read the conference call transcript
.

Amarin's stock reverse split before market open on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Amarin subsidiaries include these companies: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited.

Top institutional shareholders of Amarin include Brooklands Fund Management Ltd (1.03%), LCM Capital Management Inc (0.28%), R Squared Ltd (0.23%) and State Street Corp (0.13%). Insiders that own company stock include Aaron Berg, Steven B Ketchum and Patrick Holt.
View institutional ownership trends
.

Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Tesla (TSLA), Block (XYZ) and Canopy Growth (CGC).

Company Calendar

Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:AMRN
CIK
897448
Fax
N/A
Employees
80
Year Founded
1991

Price Target and Rating

High Price Target
$13.00
Low Price Target
$13.00
Potential Upside/Downside
+23.0%
Consensus Rating
Sell
Rating Score (0-4)
1.33
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.80 million
Net Margins
-10.87%
Pretax Margin
-9.73%
Return on Equity
-0.52%
Return on Assets
-0.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.50
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$213.65 million
Price / Sales
1.04
Cash Flow
$0.34 per share
Price / Cash Flow
31.19
Book Value
$21.09 per share
Price / Book
0.50

Miscellaneous

Outstanding Shares
21,070,000
Free Float
20,186,000
Market Cap
$222.71 million
Optionable
Optionable
Beta
0.81

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NASDAQ:AMRN) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners